invoX Pharma to Acquire UK Drugmaker F-star Therapeutics for USD 161m.

MANews-(C)2009-2022

London-based invoX Pharma, focussed on research and development and business development activities outside of China, has agreed to acquire all issued and outstanding shares of common stock of UK-based biopharmaceutical company F-star Therapeutics, Inc. (NASDAQ: FSTX) in a transaction that values F-star at approximately USD 161m, the company said.

invoX Pharma is a wholly owned subsidiary of Sino Biopharmaceutical Ltd. (HKEX 1177 HK).

The proposed USD 161m all-cash acquisition will accelerate invoX's strategy to build Sino Biopharm's International Biopharmaceutical R and D Platform outside of China.

The proposed acquisition values F-star at approximately USD 161m. The transaction is expected to close in the second half of 2022.

F-star Therapeutics, Inc. is pioneering bispecifics in immunotherapy with a proprietary platform technology pioneers the use of tetravalent bispecific antibodies that enable the simultaneous targeting of two different antigens and a unique set of pharmacology to deliver focussed, potent and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT